Andrographolide inhibits Burkitt’s lymphoma by binding JUN and CASP3 proteins Junquan ZengYongliang ZhengTingting Liu Original Article Open access 26 December 2023 Pages: 381 - 391
Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report Yoshiharu SuzukiShingo IshiguroMika Suzuki Short Communication 26 December 2023
Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway Liru HuangFuhong LiuPing Hu Original Article 23 December 2023 Pages: 203 - 213
Retraction Note: Atrial natriuretic peptide protects against cisplatin‑induced granulocytopenia Takashi NojiriHiroshi HosodaKenji Kangawa Retraction Note 21 December 2023 Pages: 271 - 271
Translational PK-PD/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule Shinji KobuchiAtsuko MoritaYukako Ito Original Article 20 December 2023 Pages: 365 - 379
Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients K. WesterdijkS. D. KrensN. P. van Erp Original Article Open access 17 December 2023 Pages: 353 - 364
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study Nobuaki MatsubaraShota KusuharaToshio Shimizu Original Article Open access 13 December 2023 Pages: 341 - 352
Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/β-catenin signaling pathway in breast cancer Shengxi XuYingfang ShiSen Li Original Article 05 December 2023 Pages: 191 - 202
Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer Xingyi LinYing TanYinting Chen Original Article 01 December 2023 Pages: 237 - 251
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study Carla BiesdorfXiaowen GuanAkshanth R. Polepally Original Article 30 November 2023 Pages: 329 - 339
Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study Hiroaki TakahashiYoko SaitoKenzo Kudo Original Article 28 November 2023 Pages: 319 - 328
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors Arjun MittraGeraldine H. O’ Sullivan CoyneAlice P. Chen Original Article Open access 27 November 2023 Pages: 177 - 189
Azithromycin in cancer treatment: envisioning the probable link of mitochondrial dysfunction and necroptosis Siti Nazihahasma HassanFarizan Ahmad Letter to the Editor 14 November 2023
Retraction Note: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis Nidhi NigamJasmine GeorgeYogeshwer Shukla Retraction Note 13 November 2023 Pages: 269 - 269
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults Yizhe ChenDavid WyattGopal Krishna Original Article Open access 13 November 2023 Pages: 307 - 317
Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy? Mourad HamimedRaynier DevillierSamia Harbi Short Communication 13 November 2023
CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms Yuanpei WangJing WenFang Ren Original Article 08 November 2023 Pages: 295 - 306
A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC? Angeline GinzacEmilie ThivatXavier Durando Original Article Open access 07 November 2023 Pages: 225 - 236
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? Martina CatalanoAndrea LapucciGiandomenico Roviello Review Article Open access 07 November 2023 Pages: 1 - 9
Effect of vitamin E on doxorubicin and paclitaxel-induced memory impairments in male rats Ahmad A. AltarifiKareem SawaliOmar Khabour Original Article 06 November 2023 Pages: 215 - 224
Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer Xinyu WangShujun GuXu Qi Original Article 05 November 2023 Pages: 151 - 159
Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report M. BergeJ. S. GiraudB. Blanchet Letter to the Editor 03 November 2023 Pages: 519 - 521
The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis Yukio TonozukaHiroshi TanakaYoshihide Kakimoto Original Article Open access 03 November 2023 Pages: 137 - 149
Are novel oral oncolytics underdosed in obese patients? Lishi LinEllen K. O. van der MeerAlwin D. R. Huitema Original Article Open access 31 October 2023 Pages: 129 - 136
Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer Yao LiangOsamu MaedaYuichi Ando Original Article 28 October 2023 Pages: 121 - 127
Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach Liangang ChenNa YaoKai Zhang Original Article 14 October 2023 Pages: 107 - 119
Bidirectional pharmacokinetic drug interactions between olaparib and metformin Joanna Stanisławiak-RudowiczAgnieszka KarbownikEdyta Szałek Original Article Open access 10 October 2023 Pages: 79 - 88
Prospective validation of an equation based on plasma cystatin C for monitoring the glomerular filtration rate in children treated with cisplatin or ifosfamide for cancer Marie LambertMathieu AlonsoEtienne Chatelut Short Communication 03 October 2023 Pages: 393 - 395
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide Sabin Goktas AydinYasin KutluOzcan Yildiz Original Article 29 September 2023 Pages: 71 - 78
Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose Bart A. JessenPaul CornwellTimothy Hart Correction Open access 29 September 2023
Long non-coding RNAs: controversial roles in drug resistance of solid tumors mediated by autophagy Mohamed J. SaadhMuhammad Ali Abdulllah AlmoyadReza Akhavan-Sigari Review Article 28 September 2023 Pages: 439 - 453
Sodium orthovanadate exhibits anti-angiogenic, antiapoptotic and blood glucose-lowering effect on colon cancer associated with diabetes Kruti PatelVivek BoraBhoomika Patel Original Article 27 September 2023 Pages: 55 - 70
Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma Hajime YasudaNaoko KagaMiki Ando Short Communication 26 September 2023 Pages: 265 - 268
Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells Man-Yuan LiJiao ZhangHong Zheng Original Article 23 September 2023 Pages: 41 - 54
Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer Mengfei ChengFang YangMei Dong Original Article 23 September 2023 Pages: 31 - 39
A phase I study of the ceramide nanoliposome in patients with advanced solid tumors Aaron CinerTheodore GourdinYixing Jiang Original Article Open access 22 September 2023 Pages: 23 - 29
TMEM120A-mediated regulation of chemotherapy sensitivity in colorectal cancer cells Li WangXiaoxia Liu Original Article 20 September 2023 Pages: 11 - 22
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes Anna Maria MilitelloGiulia OrsiMichele Reni Original Article 19 September 2023 Pages: 501 - 510
The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models Martina JabloñskiMaría Sol RodríguezIsabel Alicia Lüthy Original Article 19 September 2023 Pages: 485 - 499
Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment Mototsugu OyaShuichi KanekoYutaka Okayama Retraction Note Open access 16 September 2023 Pages: 523 - 523
Pharmacokinetics and pharmacodynamics of Rh2 and aPPD ginsenosides in prostate cancer: a drug interaction perspective Mohamed Ben-EltrikiGehana ShankarSubrata Deb Review Article 15 September 2023 Pages: 419 - 437
Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients Alireza AbbaspourMehdi DehghaniOmidreza Firuzi Original Article 05 September 2023 Pages: 475 - 483
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer Yukitaka ShibataNatsumi MatsumotoKen-ichi Fujita Original Article 31 August 2023 Pages: 465 - 474
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation Shiyu HeQianhang ShaoQian Jiang Original Article 25 August 2023 Pages: 399 - 410
Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection Cléa TardyAlicja PuszkielAudrey Thomas Schoemann Short Communication 24 August 2023 Pages: 169 - 175
Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy Junichi NakagawaTakenori TakahataTakenori Niioka Original Article 23 August 2023 Pages: 391 - 398
Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure Hirotaka ImamakiMitsuaki OuraYoshinao Ozaki Short Communication Open access 22 August 2023 Pages: 161 - 167
Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer Kenji NakahamaMotohiro IzumiTomoya Kawaguchi Original Article 22 August 2023 Pages: 381 - 390
A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype John F. MarcellettiBranimir I. Sikic Original Article 21 August 2023 Pages: 369 - 380